Fenretinide in cancer therapy and chemoprevention: past, present and future

Abstract

Fenretinide [N-(4-hydroxyphenyl) retinamide, 4-HPR] is a synthetic retinoid known for decades for its antitumor activity and favorable toxicological profile. In vitro and in vivo studies have demonstrated that fenretinide has broad-spectrum anticancer potential, eliciting multiple biological effects and acting as a multi-target compound that influences both tumor cells and the tumor microenvironment. However, the clinical application of fenretinide has been hampered by unfavorable physicochemical properties, such as poor solubility and low bioavailability, leading to highly variable outcomes in clinical studies. The development of novel fenretinide nanoformulations based on drug encapsulation in nanomicelles has helped overcome bioavailability limitations and improve anticancer efficacy in preclinical studies, thereby paving the way for new clinical opportunities. Moreover, recent studies have shown that fenretinide restrains the cancer stem cell compartment and promotes tumor cell dormancy, suggesting its potential use in dormancy-inducing strategies aimed at preventing and/or controlling metastatic disease. Here, we provide an overview of fenretinide’s mechanisms of action in cancer cells, summarize the available clinical evidence and discuss advances achieved with novel formulations. Finally, we discuss the potential integration of fenretinide at different stages of clinical management, with particular emphasis on its prospective use as a chemopreventive strategy or as a therapeutic option for disease control.

Keywords

Fenretinide / 4-HPR / tumor dormancy / nanoformulations / chemoprevention / cancer stem cells

References

[1] Jin Y,Lau HLN,Mah SH.Retinoids as anti-cancer agents and their mechanisms of action.Am J Cancer Res2022;12:938-60

[2] Gudas LJ.Retinoids regulate stem cell differentiation.J Cell Physiol2011;226:322-30 PMCID:PMC3315372

[3] Nowak D,Koeffler HP.Differentiation therapy of leukemia: 3 decades of development.Blood2009;113:3655-65 PMCID:PMC2943835

[4] Huang M,Chen S.Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.Blood1988;72:567-72

[5] Chomienne C,Balitrand N.All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship.Blood1990;76:1710-7

[6] Ulukaya E.Fenretinide and its relation to cancer.Cancer Treat Rev1999;25:229-35

[7] Hail N Jr,Lotan R.Mechanisms of fenretinide-induced apoptosis.Apoptosis2006;11:1677-94

[8] Orienti I,De Angelis ML.A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors.Cell Death Dis2019;10:529 PMCID:PMC6646369

[9] Rahmaniyan M,Obeid LM,Kraveka JM.Identification of dihydroceramide desaturase as a direct in vitro target for fenretinide.J Biol Chem2011;286:24754-64 PMCID:PMC3137051

[10] Apraiz A,Nieto-Rementería N,Hannun YA.Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death.Biochem Cell Biol2012;90:209-23 PMCID:PMC3663831

[11] Xie H,Huang Z.Identification of mammalian target of rapamycin as a direct target of fenretinide both in vitro and in vivo.Carcinogenesis2012;33:1814-21 PMCID:PMC3515856

[12] De Angelis ML,Aricò E.A nanoencapsulated oral formulation of fenretinide promotes local and metastatic breast cancer dormancy in HER2/neu transgenic mice.J Exp Clin Cancer Res2024;43:296 PMCID:PMC11536529

[13] Fazi B,Fimia GM.Fenretinide induces autophagic cell death in caspase-defective breast cancer cells.Autophagy2008;4:435-41

[14] Orienti I,Sette G.A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells.J Exp Clin Cancer Res2019;38:373 PMCID:PMC6706930

[15] Du Y,Pan X.Fenretinide targets chronic myeloid leukemia stem/progenitor cells by regulation of redox signaling.Antioxid Redox Signal2014;20:1866-80 PMCID:PMC3967369

[16] Liu L,Wang H,Du Y.Fenretinide targeting of human colon cancer sphere cells through cell cycle regulation and stress-responsive activities.Oncol Lett2018;16:5339-48 PMCID:PMC6144862

[17] Wang H,Du Y.Ovarian and breast cancer spheres are similar in transcriptomic features and sensitive to fenretinide.Biomed Res Int2013;2013:510905 PMCID:PMC3816214

[18] Zhang H,Fang H.Preferential eradication of acute myelogenous leukemia stem cells by fenretinide.Proc Natl Acad Sci U S A2013;110:5606-11 PMCID:PMC3619353

[19] Sogno I,Ferrari N.Angioprevention with fenretinide: targeting angiogenesis in prevention and therapeutic strategies.Crit Rev Oncol Hematol2010;75:2-14

[20] Wang D,Shea FF.Fenretinide combines perturbation of signaling kinases, cell-extracellular matrix interactions and matrix metalloproteinase activation to inhibit invasion in oral squamous cell carcinoma cells.Carcinogenesis2022;43:851-64 PMCID:PMC9587683

[21] Dong R,Meng W.The involvement of M2 macrophage polarization inhibition in fenretinide-mediated chemopreventive effects on colon cancer.Cancer Lett2017;388:43-53

[22] Ferrari N,Dell’Eva R,Noonan DM.The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide.Clin Cancer Res2005;11:4610-9

[23] GBD 2023 Cancer Collaborators. The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.Lancet2025;406:1565-86 PMCID:PMC12687902

[24] Francescangeli F,Rossi R.Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution.Cancer Metastasis Rev2023;42:197-215 PMCID:PMC10014678

[25] D’Alterio C,Sozzi G,Bertolini G.Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion.Semin Cancer Biol2020;60:351-61

[26] Karagiannis GS,Oktay MH.Chemotherapy-induced metastasis: molecular mechanisms, clinical manifestations, therapeutic interventions.Cancer Res2019;79:4567-76 PMCID:PMC6744993

[27] Famta P,Jain N.Tumor-promoting aftermath post-chemotherapy: a focus on breast cancer.Life Sci2022;310:121125

[28] Bedard PL,Ratain MJ.Tumour heterogeneity in the clinic.Nature2013;501:355-64 PMCID:PMC5224525

[29] Jamal-Hanjani M,Larkin J.Translational implications of tumor heterogeneity.Clin Cancer Res2015;21:1258-66 PMCID:PMC4374162

[30] Lawson DA,Davis RT,Werb Z.Tumour heterogeneity and metastasis at single-cell resolution.Nat Cell Biol2018;20:1349-60 PMCID:PMC6477686

[31] Lüönd F,Christofori G.Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression.Br J Cancer2021;125:164-75 PMCID:PMC8292450

[32] Huang S.How to escape the cancer attractor: rationale and limitations of multi-target drugs.Semin Cancer Biol2013;23:270-8

[33] Doostmohammadi A,Ghorbanian K,Dadashpour M.Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents.Cell Commun Signal2024;22:228 PMCID:PMC11020265

[34] Torrisi R.Fenretinide and cancer prevention.Curr Oncol Rep2000;2:263-70

[35] Delia D,Lombardi L.N-(4-hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid.Cancer Res1993;53:6036-41

[36] Mariotti A,Bunone G.N-(4-hydroxyphenyl)retinamide: a potent inducer of apoptosis in human neuroblastoma cells.J Natl Cancer Inst1994;86:1245-7

[37] Yan W,Du Y.Fenretinide targets the side population in myeloma cell line NCI-H929 and potentiates the efficacy of antimyeloma with bortezomib and dexamethasone regimen.Leuk Res2016;51:32-40

[38] Veronesi U,Decensi A.Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer.Ann Oncol2006;17:1065-71

[39] Villablanca JG,Naranjo A.Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children’s Oncology Group.Clin Cancer Res2011;17:6858-66 PMCID:PMC3207022

[40] Jasti BR,Parchment RE.Phase I clinical trial of fenretinide (NSC374551) in advanced solid tumors.Proc Am Soc Clin Oncol2001;20:122a

[41] Potenza RL,Orienti I.Fenretinide in cancer and neurological disease: a two-face Janus molecule.Int J Mol Sci2022;23:7426 PMCID:PMC9266536

[42] Cooper JP,Cho H.Clinical development of fenretinide as an antineoplastic drug: pharmacology perspectives.Exp Biol Med2017;242:1178-84 PMCID:PMC5478002

[43] Le Doze F, Debruyne D, Albessard F, Barre L, Defer GL. Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat.Drug Metab Dispos2000;28:205-8

[44] Alfei S.Attempts to improve lipophilic drugs’ solubility and bioavailability: a focus on fenretinide.Pharmaceutics2024;16:579 PMCID:PMC11125266

[45] Simeone AM.How retinoids regulate breast cancer cell proliferation and apoptosis.Cell Mol Life Sci2004;61:1475-84 PMCID:PMC11138852

[46] Lovat PE,Corazzari M.Gangliosides link the acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxygenase-dependent apoptosis of neuroblastoma in response to fenretinide.J Natl Cancer Inst2004;96:1288-99

[47] Bassani B,Pagani A.Fenretinide (4-HPR) targets caspase-9, ERK 1/2 and the Wnt3a/β-catenin pathway in medulloblastoma cells and medulloblastoma cell spheroids.PLoS One2016;11:e0154111 PMCID:PMC4930187

[48] Fanjul AN,Pierotti MA,Yu JQ.4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors.J Biol Chem1996;271:22441-6

[49] Bu P.Fenretinide-induced apoptosis of Huh-7 hepatocellular carcinoma is retinoic acid receptor beta dependent.BMC Cancer2007;7:236 PMCID:PMC2249606

[50] Yang H,Bu P.Induction and intracellular localization of Nur77 dictate fenretinide-induced apoptosis of human liver cancer cells.Biochem Pharmacol2010;79:948-54 PMCID:PMC2832928

[51] Xiong J,Lu T.Fenretinide-induced apoptosis of acute myeloid leukemia cells via NR4A1 translocation into mitochondria and Bcl-2 transformation.J Cancer2019;10:6767-78 PMCID:PMC6909957

[52] Yang H,Wan YJ.Enrichment of Nur77 mediated by retinoic acid receptor β leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors.Hepatology2011;53:865-74 PMCID:PMC3077573

[53] Lovat PE,Annichiarrico-Petruzzelli M.Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma.Exp Cell Res2000;260:50-60

[54] Ulukaya E,Kurt MA,Mehmet H.Fenretinide induces cytochrome c release, caspase 9 activation and apoptosis in the absence of mitochondrial membrane depolarisation.Cell Death Differ2003;10:856-9

[55] Kim YK.The mitochondrial PKCδ/retinol signal complex exerts real-time control on energy homeostasis.Biochim Biophys Acta Mol Cell Biol Lipids2020;1865:158614 PMCID:PMC7347429

[56] Di Paola M, Cocco T, Lorusso M. Ceramide interaction with the respiratory chain of heart mitochondria.Biochemistry2000;39:6660-8

[57] Gentil B,Riva C.Commitment to apoptosis by ceramides depends on mitochondrial respiratory function, cytochrome c release and caspase-3 activation in Hep-G2 cells.Mol Cell Biochem2003;254:203-10

[58] Cuperus R,Tytgat GA,van Kuilenburg AB.Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma.Cell Mol Life Sci2010;67:807-16 PMCID:PMC2824117

[59] Magaye RR,Hua Y.The role of dihydrosphingolipids in disease.Cell Mol Life Sci2019;76:1107-34 PMCID:PMC11105797

[60] Lachkar F,Foufelle F.Dihydroceramides: their emerging physiological roles and functions in cancer and metabolic diseases.Am J Physiol Endocrinol Metab2021;320:E122-30

[61] Erdreich-Epstein A,Bowman NN.Ceramide signaling in fenretinide-induced endothelial cell apoptosis.J Biol Chem2002;277:49531-7

[62] Rehman F,Schrey MP.Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity.Br J Cancer2004;91:1821-8 PMCID:PMC2410057

[63] Kraveka JM,Szulc ZM.Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells.J Biol Chem2007;282:16718-28 PMCID:PMC2084375

[64] Zheng W,Symolon H.Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy.Biochim Biophys Acta2006;1758:1864-84

[65] Wang H,Liu YY.N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing.Mol Cancer Ther2008;7:2967-76

[66] Valsecchi M,Mauri L.Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids.J Lipid Res2010;51:1832-40 PMCID:PMC2882740

[67] Hernández-Tiedra S,Dávila D.Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization.Autophagy2016;12:2213-29 PMCID:PMC5103338

[68] Tian T,Zhang J.mTOR Signaling in cancer and mTOR inhibitors in solid tumor targeting therapy.Int J Mol Sci2019;20:755 PMCID:PMC6387042

[69] Benelli R,Venè R,Ferrari N.The chemopreventive retinoid 4HPR impairs prostate cancer cell migration and invasion by interfering with FAK/AKT/GSK3beta pathway and beta-catenin stability.Mol Cancer2010;9:142 PMCID:PMC2898704

[70] Cao J,Wang D.ROS-driven Akt dephosphorylation at Ser-473 is involved in 4-HPR-mediated apoptosis in NB4 cells.Free Radic Biol Med2009;47:536-47

[71] Kaur J.Autophagy at the crossroads of catabolism and anabolism.Nat Rev Mol Cell Biol2015;16:461-72

[72] Liu S,Yang H,Wang Y.Autophagy: regulator of cell death.Cell Death Dis2023;14:648 PMCID:PMC10551038

[73] Tiwari M,Sahasrabuddhe AA.Inhibition of N-(4-hydroxyphenyl)retinamide-induced autophagy at a lower dose enhances cell death in malignant glioma cells.Carcinogenesis2008;29:600-9

[74] Bonnet D.Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.Nat Med1997;3:730-7

[75] Lapidot T,Vormoor J.A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.Nature1994;367:645-8

[76] Singh SK,Clarke ID.Identification of human brain tumour initiating cells.Nature2004;432:396-401

[77] Collins AT,Hyde C,Maitland NJ.Prospective identification of tumorigenic prostate cancer stem cells.Cancer Res2005;65:10946-51

[78] Ricci-Vitiani L,Pilozzi E.Identification and expansion of human colon-cancer-initiating cells.Nature2007;445:111-5

[79] Dembinski JL.Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma.Clin Exp Metastasis2009;26:611-23 PMCID:PMC2776152

[80] Al-Hajj M,Benito-Hernandez A,Clarke MF.Prospective identification of tumorigenic breast cancer cells.Proc Natl Acad Sci U S A2003;100:3983-8 PMCID:PMC153034

[81] Eramo A,De Maria R.Lung cancer stem cells: tools and targets to fight lung cancer.Oncogene2010;29:4625-35

[82] Aleksandrova KV,Suvorova II.mTOR pathway occupies a central role in the emergence of latent cancer cells.Cell Death Dis2024;15:176 PMCID:PMC10902345

[83] Safa AR.Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces.Cancer Drug Resist2022;5:850-72 PMCID:PMC9771762

[84] Jia H,Zheng W.The dual role of autophagy in cancer stem cells: implications for tumor progression and therapy resistance.J Transl Med2025;23:583 PMCID:PMC12105148

[85] Nazio F,Cianfanelli V,Cecconi F.Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications.Cell Death Differ2019;26:690-702 PMCID:PMC6460398

[86] Castaigne S,Daniel MT.All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results.Blood1990;76:1704-9

[87] Warrell RP Jr,Miller WH Jr.Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).N Engl J Med1991;324:1385-93

[88] McKenzie MD,Oxley EP.Interconversion between tumorigenic and differentiated states in acute myeloid leukemia.Cell Stem Cell2019;25:258-72.e9

[89] Carvalho J.Cell reversal from a differentiated to a stem-like state at cancer initiation.Front Oncol2020;10:541 PMCID:PMC7174973

[90] Hanahan D.Hallmarks of cancer: new dimensions.Cancer Discov2022;12:31-46

[91] Pérez-González A,Blanpain C.Cancer cell plasticity during tumor progression, metastasis and response to therapy.Nat Cancer2023;4:1063-82 PMCID:PMC7615147

[92] Farruggia G,Galassi L.Nano-fenretinide demonstrates remarkable activity in acute promyeloid leukemia cells.Sci Rep2024;14:13737 PMCID:PMC11178801

[93] Diehn M,Lobo NA.Association of reactive oxygen species levels and radioresistance in cancer stem cells.Nature2009;458:780-3 PMCID:PMC2778612

[94] Villani MG,Cavadini E.4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.Cancer Res2006;66:3238-47

[95] Oki T,Kitaura J.A novel cell-cycle-indicator, mVenus-p27K-, identifies quiescent cells and visualizes G0-G1 transition.Sci Rep2014;4:4012 PMCID:PMC3915272

[96] Aguirre-Ghiso JA,Liu D.ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK).Cancer Res2003;63:1684-95

[97] Agudo J,Bhatia M,Correia AL.Targeting cancer cell dormancy.Nat Rev Cancer2024;24:97-104 PMCID:PMC11038906

[98] Balayan V.Tumor dormancy: biologic and therapeutic implications.World J Oncol2022;13:8-19 PMCID:PMC8913011

[99] Hensel JA,Theodorescu D.Clinical opportunities and challenges in targeting tumour dormancy.Nat Rev Clin Oncol2013;10:41-51

[100] Aguirre-Ghiso JA.Models, mechanisms and clinical evidence for cancer dormancy.Nat Rev Cancer2007;7:834-46 PMCID:PMC2519109

[101] Wang Y,Zhang X,Bai X.Cancer dormancy and metabolism: from molecular insights to translational opportunities.Cancer Lett2025;635:218097

[102] Li X,Pennisi A,Yaccoby S.Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.Cancer Lett2009;284:175-81 PMCID:PMC2743080

[103] Pienta KJ,Lehr JE.Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide.Cancer Res1993;53:224-6

[104] Tosetti F,Arena G.N-(4-hydroxyphenyl)retinamide inhibits retinoblastoma growth through reactive oxygen species-mediated cell death.Mol Pharmacol2003;63:565-73

[105] Ferrari N,Pfeffer U,Noonan DM.Inhibition of Kaposi’s sarcoma in vivo by fenretinide.Clin Cancer Res2003;9:6020-9

[106] Simile MM,Pastorino F.Chemopreventive N-(4-hydroxyphenyl)retinamide (fenretinide) targets deregulated NF-κB and Mat1A genes in the early stages of rat liver carcinogenesis.Carcinogenesis2005;26:417-27

[107] Reynolds CP.Retinoid therapy of childhood cancer.Hematol Oncol Clin North Am2001;15:867-910

[108] Nieto K,Wang D,Schwendeman SP.In vivo controlled release of fenretinide from long-acting release depots for chemoprevention of oral squamous cell carcinoma recurrence.Int J Pharm2018;538:48-56 PMCID:PMC6460921

[109] Garaventa A,Lo Piccolo MS.Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.Clin Cancer Res2003;9:2032-9

[110] Liu X,Frgala T. Preclinical toxicology and pharmacokinetics of intravenous lipid emulsion fenretinide. Mol Cancer Ther. 2007;6:C159. Available from: https://aacrjournals.org/mct/article/6/11_Supplement/C159/240578/Preclinical-toxicology-and-pharmacokinetics-of?guestAccessKey=. [Last accessed on 2 Jun 2026]

[111] Vaishampayan U,Parchment RE.Phase II trial of fenretinide in advanced renal carcinoma.Invest New Drugs2005;23:179-85

[112] Schneider BJ,Gadgeel SM.Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer.Invest New Drugs2009;27:571-8

[113] Cheung E,Dorff T.Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.Clin Genitourin Cancer2009;7:43-50

[114] Moore MM,Lim R,Millward M.A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group.Cancer Chemother Pharmacol2010;66:845-50

[115] Puduvalli VK, Yung WK, Hess KR, et al.; North American Brain Tumor Consortium. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.J Clin Oncol2004;22:4282-9 PMCID:PMC3820102

[116] Colombo N,Cantù MG.A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.Cancer Epidemiol Biomarkers Prev2006;15:1914-9

[117] Reynolds CP,Tsao-Wei DD.High plasma levels of fenretinide (4-HPR) were associated with improved outcome in a phase II study of recurrent ovarian cancer: a study by the California Cancer Consortium.J Clin Oncol2007;25:5555

[118] Modiano MR,Lippman SM,Booth AR.Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma.Invest New Drugs1990;8:317-9

[119] Maurer BJ,Yesair DW.Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.Clin Cancer Res2007;13:3079-86

[120] Kummar S,Maurer BJ.Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas.Anticancer Res2011;31:961-6 PMCID:PMC7357208

[121] Maurer BJ,Villablanca JG.Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.Pediatr Blood Cancer2013;60:1801-8 PMCID:PMC4066886

[122] Maurer BJ,Kang MH.Fenretinide (4-HPR)/Lym-X-Sorb (LXS) oral powder plus ketoconazole in patients with high-risk (HR) recurrent or resistant neuroblastoma: a new approach to Neuroblastoma Therapy (NANT) Consortium trial.J Clin Oncol2014;32:10071

[123] Lopez-Barcons L,Kang MH.P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.Int J Cancer2017;141:405-13

[124] Thomas JS,Maurer BJ.A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors.Cancer Chemother Pharmacol2021;87:525-32 PMCID:PMC8058950

[125] Mohrbacher AM,Groshen S.Phase I study of fenretinide delivered intravenously in patients with relapsed or refractory hematologic malignancies: a California Cancer Consortium trial.Clin Cancer Res2017;23:4550-5 PMCID:PMC5559312

[126] Galassi L,Lodeserto P.Naxitamab activity in neuroblastoma cells is enhanced by nanofenretinide and nanospermidine.Pharmaceutics2023;15:648 PMCID:PMC9966923

[127] Lodeserto P,Blasi P,Orienti I.Nanospermidine in combination with nanofenretinide induces cell death in neuroblastoma cell lines.Pharmaceutics2022;14:1215 PMCID:PMC9229898

[128] Orienti I,Nguyen F.Nanomicellar lenalidomide-fenretinide combination suppresses tumor growth in an MYCN amplified neuroblastoma tumor.Int J Nanomedicine2020;15:6873-86 PMCID:PMC7502401

[129] Orienti I,Guan P.A novel nanomicellar combination of fenretinide and lenalidomide shows marked antitumor activity in a neuroblastoma xenograft model.Drug Des Devel Ther2019;13:4305-19 PMCID:PMC6930389

[130] Ozpolat B,Mehta K.Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells.Leuk Lymphoma2004;45:979-85

[131] Nguyen TH,Wei SJ.Fenretinide via NOXA induction, enhanced activity of the BCL-2 inhibitor venetoclax in high BCL-2-expressing neuroblastoma preclinical models.Mol Cancer Ther2019;18:2270-82 PMCID:PMC9255909

[132] Fang H,Kalous O,DeClerck YA.Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.Clin Cancer Res2011;17:7093-104 PMCID:PMC4193939

[133] Magwere T,Burchill SA.Manipulation of oxidative stress to induce cell death in Ewing’s sarcoma family of tumours.Eur J Cancer2008;44:2276-87

[134] Faes S,Dormond O.Resistance to mTORC1 inhibitors in cancer therapy: from kinase mutations to intratumoral heterogeneity of kinase activity.Oxid Med Cell Longev2017;2017:1726078 PMCID:PMC5322438

[135] Roundhill EA.Detection and characterisation of multi-drug resistance protein 1 (MRP-1) in human mitochondria.Br J Cancer2012;106:1224-33 PMCID:PMC3304412

[136] SciTech Development Inc. SciTech development advances to next stage of clinical trial for ST-001 nanoFenretinide. 2025. Available from: https://www.prnewswire.com/news-releases/scitech-development-advances-to-next-stage-of-clinical-trial-for-st-001-nanofenretinide-302348501.html. [Last accessed on 2 Jun 2026]

[137] Riggio AI,Welm AL.The lingering mysteries of metastatic recurrence in breast cancer.Br J Cancer2021;124:13-26 PMCID:PMC7782773

[138] Rueda OM,Seoane JA.Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.Nature2019;567:399-404 PMCID:PMC6647838

[139] DeMichele A,Shea E.Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial.Nat Med2025;31:3464-74

[140] Pedersen RN,Mellemkjær L.The incidence of breast cancer recurrence 10-32 years after primary diagnosis.J Natl Cancer Inst2022;114:391-9 PMCID:PMC8902439

[141] Formelli F.Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line.Eur J Cancer2000;36:2411-9

[142] Kalemkerian GP.Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines.Cancer Chemother Pharmacol1999;43:145-50

[143] Hill DS,Armstrong JL.Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma.Clin Cancer Res2009;15:1192-8 PMCID:PMC2917762

[144] Cowan AJ,Press OW.Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.Anticancer Drugs2015;26:974-83 PMCID:PMC4545689

[145] Pagnan G,Carosio R.The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.Clin Cancer Res2009;15:1199-209

[146] Liu J,Zhang JF.Combination of fenretinide and selenite inhibits proliferation and induces apoptosis in ovarian cancer cells.Int J Mol Sci2013;14:21790-804 PMCID:PMC3856035

[147] Britt EL,Leek K,Kim SW.Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment.PLoS One2019;14:e0219398 PMCID:PMC6611623

[148] Makena MR,Nguyen TH,Reynolds CP.Reactive oxygen species-mediated synergism of fenretinide and romidepsin in preclinical models of T-cell lymphoid malignancies.Mol Cancer Ther2017;16:649-61

[149] Makena MR,Koneru B.Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies.Anticancer Drugs2021;32:34-43

[150] Gopal AK,Hedin N.Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism.Blood2004;103:3516-20

[151] Cowan AJ,Gooley TA.Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma.Br J Haematol2017;176:583-90 PMCID:PMC5303179

[152] Decensi A,Guerrieri-Gonzaga A.Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.J Clin Oncol2009;27:3749-56 PMCID:PMC2799048

[153] Otterson GA,Villalona-Calero MA.A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors.Invest New Drugs2005;23:555-62